CD19 and B-cell non-Hodgkin lymphoma: CD19-directed CAR T-cell (CART19) therapy has been approved for B-cell malignancies including B-cell precursor acute lymphoblastic leukemia (B-ALL), high-grade B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (5–14).